EP Patent

EP3998069A1 — Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors

Assigned to Abraxis Bioscience LLC · Expires 2022-05-18 · 4y expired

What this patent protects

Provided herewith is a composition comprising an effective amount of nanoparticles comprising an mTOR inhibitor and an albumin for use in a method of treating an epithelioid tumor in an individual. Particularly, the epithelioid tumor to be treated may be a perivascular epithelioi…

USPTO Abstract

Provided herewith is a composition comprising an effective amount of nanoparticles comprising an mTOR inhibitor and an albumin for use in a method of treating an epithelioid tumor in an individual. Particularly, the epithelioid tumor to be treated may be a perivascular epithelioid cell tumor (PEComa).

Drugs covered by this patent

Patent Metadata

Patent number
EP3998069A1
Jurisdiction
EP
Classification
—
Expires
2022-05-18
Drug substance claim
No
Drug product claim
No
Assignee
Abraxis Bioscience LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.